The blockbuster weight-loss drug Wegovy, long available as an injectable, is now hitting the market in a brand-new, easier-to-take form: an oral pill.
Approved by the FDA in December 2025, this new formulation of semaglutide, the active ingredient in Wegovy, could change the way millions of Americans approach weight management. For many patients, it could mean fewer injections, lower prices, and better long-term adherence.
So what makes the Wegovy pill such a big deal, and is it really as effective as the shot?
The Wegovy pill is the first oral GLP-1 (glucagon-like peptide-1 receptor agonist) approved in the U.S. specifically for weight loss. GLP-1s help regulate appetite, blood sugar, and insulin levels, and are already well-known in diabetes and obesity treatment.
Like the injectable version, the pill is designed to be used alongside a reduced-calorie diet and increased physical activity.
Is the Wegovy Pill as Effective as the Injection?
Yes, almost.
According to clinical trial data submitted to the FDA, patients taking the Wegovy pill lost an average of 13.6% of their body weight over 15 months. That’s remarkably close to the 15% average weight loss seen with the injectable version.
The side effect profile was also similar, with common issues including nausea, vomiting, constipation, and fatigue, especially during dose escalation periods.
For many patients who are reluctant to self-inject or who struggle with supply issues for the injectable version, the pill could offer a nearly equal alternative — without the needle.
How Much Does the Wegovy Pill Cost?
Here’s where things get interesting: the Wegovy pill is priced lower than the injectable version, especially for self-pay patients accessing the drug through telehealth providers or Novo Nordisk’s direct NovoCare platform.
Wegovy Pill Pricing (2026, U.S. Self-Pay)
By comparison, the injectable version starts at $199/month and rises to $349/month for maintenance doses.
Is It Covered by Insurance?
Coverage remains complicated and frustratingly inconsistent.
While some commercial insurers do cover GLP-1s like Wegovy, coverage for weight loss (as opposed to diabetes) is still limited.
According to a 2024 survey by the International Foundation of Employee Benefit Plans (IFEBP):
- 55% of U.S. employers cover GLP-1s for diabetes only
- Only 36% cover them for both diabetes and weight loss
- Of those covering diabetes only, just 17% were considering expanding coverage to include obesity treatment
Insurance plans often exclude obesity drugs due to high costs and concerns about long-term adherence. Many patients are still paying out-of-pocket.
View this post on Instagram
Novo Nordisk offers savings cards that can bring the monthly cost of Wegovy down to as little as $25 for eligible patients, but this typically applies only after high deductibles are met, and only if your insurance already covers the drug.
Where Can You Get the Wegovy Pill?
The pill is now available in pharmacies nationwide and can also be ordered via telehealth platforms, which have become a major access point for weight-loss medications in recent years.
You can also obtain it through NovoCare, the official direct-to-patient program from Novo Nordisk, which streamlines access, offers consultations, and provides transparent pricing.
Why GLP-1 Drugs Like Wegovy Are Reshaping the Weight-Loss Industry?
The Wegovy pill isn’t launching in a vacuum. It enters a rapidly expanding market for GLP-1 weight-loss drugs, which have surged in popularity since 2022.
According to a 2025 KFF health policy report:
Roughly 1 in 8 U.S. adults are now using a GLP-1 drug for weight loss, diabetes, or both.
That number is likely to grow. With nearly 40% of American adults classified as obese, the demand for accessible, effective weight management tools is skyrocketing.
Beyond Weight Loss: Other Approved Uses of GLP-1s
GLP-1s, including Wegovy, are now being explored and approved for a wide range of conditions, including:
- Type 2 Diabetes
- Cardiovascular disease risk reduction
- Chronic kidney disease
- Obstructive sleep apnea
- MASH (Metabolic dysfunction-associated steatohepatitis, formerly NAFLD)
But Do People Actually Stick With It?
@abcnewslive The first and only oral GLP-1 for weight loss in adults is now available to consumers. Consumers with prescriptions may pick up the new Wegovy pill at pharmacies nationwide or have it delivered through telehealth companies, according to Novo Nordisk. #Wegovy ♬ original sound – ABC News Live
One of the biggest concerns with GLP-1s isn’t how well they work — it’s how long people stay on them.
A 2025 study from pharmacy benefit manager Prime Therapeutics found that many patients without diabetes stop taking GLP-1s within the first two years, often due to cost, side effects, or unrealistic expectations.
However, a follow-up analysis in late 2024 showed improved persistence rates for injectables like Wegovy and Zepbound, possibly due to better education and better side effect management.
The launch of easier-to-take oral pills like Wegovy could help even more people stay on treatment longer, improving long-term outcomes and reducing weight regain.
What’s Next? Competition Is Heating Up
Novo Nordisk isn’t alone in this space.
Eli Lilly is expected to launch its own oral weight-loss drug, orforglipron, later this year — priced competitively at $149/month for starter doses, with additional doses up to $399/month.
